Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-MSC for COVID-19-Induced ARDS
NCT04728698Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Mar 2021
- Primary completion
- Sep 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of COVI-MSC in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), sponsored by Sorrento Therapeutics. Planned start Mar 2021; status: withdrawn.
02
Drugs
COVI-MSC
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04728698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728698.